4D Molecular Therapeutics

FDMT

時価総額 $6.71億

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company's board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shares of the Company's common stock and 157,600 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $12.36, which was the closing trading price on October 13, 2026, the date of grant. The stock options and RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.

4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet AMD studies are expected in Q2 and H2 2027, supporting regulatory filings for both wet AMD. Phase 2b and SPECTRA data show 4D-150 reduces injection burden by up to 87% in wet AMD and 61% in DME, with the potential to disrupt the $14B+ anti-VEGF market.

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company's board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September:

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 11, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 35,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.98 per share a year ago.